Phosphoethanolamine Blood Level Prediction for Depression Drug Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current depression treatment drug prescriptions are subjective and often ineffective, leading to prolonged disease duration, side effects, and increased economic burden, as they are not directly linked to biological indicators.
Innovation Solution
A method involving measuring blood phosphoethanolamine levels to objectively predict the effectiveness of serotonin/noradrenaline reuptake inhibitors (SNRIs) as depression treatment drugs, where a level below 1.5 µM indicates a decreased phosphoethanolamine level, prompting the selection and evaluation of SNRIs for treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If depression treatment drugs are prescribed based on subjective symptoms and doctor's judgment, then treatment flexibility is maintained, but treatment effectiveness decreases and disease duration prolongs
Solution Approach 1:
The patent performs phosphoethanolamine level measurement before prescribing treatment to predict which antidepressant class will be most effective. This preliminary biological assessment guides drug selection in advance, avoiding trial-and-error prescribing and reducing the time to effective treatment.
Solution Approach 2:
The patent uses blood phosphoethanolamine levels as a biological feedback marker to objectively assess depression severity and predict treatment response. This feedback mechanism replaces subjective symptom assessment with an objective biological indicator that correlates with treatment outcomes.
2Adaptability or versatility
If multiple antidepressant trials are conducted to find effective treatment, then treatment options are explored, but side effects increase and economic burden rises
Solution Approach 1:
The patent performs phosphoethanolamine level measurement before prescribing treatment to predict which antidepressant class will be most effective. This preliminary biological assessment guides drug selection in advance, avoiding trial-and-error prescribing and reducing the time to effective treatment.
3Ease of operation
If subjective diagnostic criteria are used, then diagnosis flexibility is maintained, but diagnostic precision decreases
Solution Approach 1:
The patent introduces blood phosphoethanolamine level as an intermediary biological marker that objectively reflects depression severity and treatment response. This intermediary measurement bridges the gap between subjective symptoms and objective treatment outcomes, providing a quantifiable diagnostic criterion.
Data Source
AI summary
[Problem] To provide a method in which a phosphoethanolamine (PEA), which is a biomarker of depression, is directly linked to treatment. [Solution] A method for predicting options of depression treatment drugs of the present invention comprises the following steps: (1) measuring a PEA level in blood collected from a patient suspected of depression; (2) measuring whether the blood PEA level of the patient is lower than a reference value or not, wherein if the measured value of the patient is lower than values of healthy persons, the patient suffers from depression exhibiting a decreased PEA level as an indicator; and (3) predicting options of depression treatment drugs on the basis of the presence or absence of decreased blood PEA level in the patient.